EcoDrugPlus

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSXETG00000004845
Gene Symbol: BRAF
24 Enzyme and pathways 5 View Cross-references
220 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

B-Cell Cll/lymphoma 2

Ensembl ID : ENSXETG00000035771
Gene Symbol: BCL2
4 Enzyme and pathways 5 View Cross-references
227 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Bcl2 Like 1

Ensembl ID : ENSXETG00000043454
Gene Symbol: BCL2L1
9 Enzyme and pathways 5 View Cross-references
289 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Bcl2-Like 2

Ensembl ID : ENSXETG00000014599
Gene Symbol: BCL2L2
5 View Cross-references
64 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Bcr, Rhogef And Gtpase Activating Protein

Ensembl ID : ENSXETG00000004215
Gene Symbol: BCR
10 Enzyme and pathways 5 View Cross-references
275 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Bruton Tyrosine Kinase

Ensembl ID : ENSXETG00000018152
Gene Symbol: BTK
15 Enzyme and pathways 5 View Cross-references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-X-C Motif Chemokine Ligand 8a Gene 1

Ensembl ID : ENSXETG00000044014
Gene Symbol: CXCL8A.1
15 Enzyme and pathways 5 View Cross-references
178 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-X-C Motif Chemokine Ligand 8a Gene 2

Ensembl ID : ENSXETG00000049446
Gene Symbol: CXCL8A.2
15 Enzyme and pathways 5 View Cross-references
178 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-X-C Motif Chemokine Ligand 8b Gene 2

Ensembl ID : ENSXETG00000035535
Gene Symbol: CXCL8B.2
15 Enzyme and pathways 5 View Cross-references
178 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-X-C Motif Chemokine Receptor 2

Ensembl ID : ENSXETG00000048756
Gene Symbol: CXCR2
11 Enzyme and pathways 5 View Cross-references
275 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-X-C Motif Chemokine Receptor 4

Ensembl ID : ENSXETG00000041940
Gene Symbol: CXCR4
8 Enzyme and pathways 5 View Cross-references
283 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

C-Reactive Protein

Ensembl ID : ENSXETG00000046147
Gene Symbol: LOC100494645
4 View Cross-references
545 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).